Effect of pravastatin on erythrocyte rheological and biochemical properties in poorly controlled Type 2 diabetic patients

Diabetic Medicine

Volumn 16, Issue 5, 1999, Pages 424-430

  Miossec, P ^a   Zkhiri, F ^a   Paries J ^a   David Dufilho, M ^a,b   Devynck, M A ^a,b   Valensi, Paul E ^a,c  

^a UNIVERSITÉ PARIS 13   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c HÔPITAL JEAN VERDIER   (France)

Author keywords

Blood rheology; Erythrocytes; Lipid lowering agent; Statin; Type 2 diabetes mellitus

Indexed keywords

PRAVASTATIN;

ADULT; AGED; ARTICLE; CHOLESTEROL METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ERYTHROCYTE DEFORMABILITY; ERYTHROCYTE MEMBRANE; HUMAN; LIPID COMPOSITION; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL;

ANTICHOLESTEREMIC AGENTS; BLOOD PRESSURE; CHOLESTEROL; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ELECTROLYTES; ERYTHROCYTE DEFORMABILITY; ERYTHROCYTE MEMBRANE; ERYTHROCYTES; FEMALE; FRUCTOSAMINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PHOSPHOLIPIDS; PLACEBOS; PRAVASTATIN; REFERENCE VALUES; RHEOLOGY;

EID: 0032749249     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.1999.00083.x     Document Type: Article

References (37)

1. 1 Juhan-Vague I. Déformabilité des globules rouges et diabète. Rev Méd Int 1984; (numéro hors série): 61-64.
2. 2 Koutsouris K, Delatour-Hanss E, Hanss M. Physico-chemical factors of erythrocyte deformability. Biorheology 1985; 22: 119-132.
3. 3 Stuart J, Juhan-Vague I. Erythrocyte rheology in diabetes mellitus. Clin Hemorheol 1987; 7: 239-245.
4. 4 Otsuji S, Baba Y, Kamada T. Erythrocyte membrane microviscosity in diabetes. Horm Metab Res 1981; 11: 97-102.
5. 5 Bryszewska M, Watala C, Torzecka W. Changes in fluidify and composition of erythrocyte membranes and in composition of plasma lipids in type 1 diabetes. Br J Haematol 1986; 62: 111-116.
6. 6 Berlin E, Bhathena SJ, Judd JT, Nair PP, Jones DY, Taylor PR. Dietary fat and hormonal effects on erythrocyte membrane fluidity and lipid composition in adult women. Metabolism 1989; 38: 790-796.
7. +-pump activity in erythrocytes of rabbits fed cholesterol. Int J Exp Path 1995; 76: 93-96.
8. 1-pumping activity in erythrocytes from IDDM and NIDDM subjects. Diabetes 1989; 38: 825-831.
9. 9 Schmid-Schönbein H, Volger E. Red-cell aggregation and red-cell deformability in diabetes. Diabetes 1976; 25: 897-902.
10. 10 Resnick LM, Altura BT, Gupta RK, Laragh JH, Alderman MH, Altura BM. Intracellular and extracellular magnesium depletion in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1993; 36: 767-770.
11. 11 Barbagallo M, Gupta RK, Resnick LM. Cellular ionic effects of insulin in normal human erythrocytes: a nuclear magnetic resonance study. Diabetologia 1993; 36: 146-149.
12. 12 Muzulu SI, Bing RF, Norman RI, Burden AC. Human red cell membrane fluidity and calcium pump activity in normolipidaemic type 2 diabetic subjects. Diabetic Med 1994; 11: 763-767.
13. 13 Hanss M, Attali JR, Helou C. Erythrocyte deformability and diabetes. Clin Hemorheol 1983; 3: 383-391.
14. 14 Garnier M, Attali JR, Valensi P, Delatour-Hanss E, Gaudey F, Koutsouris D. Erythrocyte deformability in diabetes and erythrocyte membrane lipid composition. Metabolism 1990; 39: 794-798.
15. 15 Garnier M, Zkhiri F, Marc B, Pariès J, Attali JR, Valensi P. Red blood cell sodium content in NID diabetic patients with hemorheological abnormalities. Clin Hemorheol 1995; 15: 325-333.
16. 16 Levy Y, Leibowitz R, Aviram M, Brook JG, Cogan U. Reduction of plasma cholesterol by lovastatin normalizes erythrocyte membrane fluidity in patients with severe hypercholesterolaemia. Br J Clin Pharmacal 1992; 34: 427-430.
17. 17 Koppensteiner R, Minar E, Ehringer H. Effect of lovastatin on hemorheology in type II hyperlipoproteinemia. Atherosclerosis 1990; 83: 53-58.
18. 18 Burnstein M, Scholnick HR, Morfin R. Rapid method for the isolation of Lipoproteins from human serum by precipitation with polyanion. J Lipid Res 1970; 11:583-595.
19. 2+-indicator fura-2. Cell Calcium 1988; 9: 167-179.
20. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260: 3440-3450.
21. 2+ concentration in essential hypertension. Hypertension 1992; 19: 167-164.
22. 22 Dodge JT, Mitchell C, Hanahan DJ. The preparation and chemical characterizations of the hemoglobin free ghosts of human erythrocytes. Arch Biochem Biophys 1963; 100: 110-119.
23. 23 Lowry O, Rosenbrough N, Farr A, Randall RJ. Protein dosage with the Folin phenol reagent. J Biol Chem 1951; 193:265-275.
24. 24 Pré J, Garnier M. Résolution quantitative rapide de chromatogrammes en couche mince de lipides plasmatiques et érythrocytaires. Pathol Biol 1973; 21: 1147-1150.
25. 25 Lijnen P, Fagard R, Staessen J, Thijs L, Amery A. Erythrocyte membrane lipids and cationic transport systems in men. J Hypertens 1992; 10: 1205-1211.
26. 26 Ruiz-Gurtierrez V, Stiefel P, Villar J, Garcia-Donas MA, Acosta D, Carneado J.Cell membrane fatty acid composition in type 1 (insulin-dependent) diabetic patients; relationship with sodium transport abnormalities and metabolic control. Diabetologia 1993; 36: 850-856.
27. 27 Juhan-Vague I, Roul C, Rahmani-Jourdheil D, Mishal Z, Driss F, Durand-Gasselin M et al. Rapid modifications of biophysical and biochemical parameters of red blood cell membrane from insulin dependent diabetics after insulin administration. Klin Wochenschr 1986; 64: 1046-1049.
28. 28 Juhan-Vague I, Driss F, Roul C, Darcet Ph, Aillaud MF, Vague P. Abnormalities of erythrocyte membrane lipids in insulin-dependent diabetics are improved by short term strict control of diabetes. Clin Hemorheol 1984; 4: 455-459.
29. 29 Kanakaraj P, Singh M. Influence of cholesterol-enrichment under in vivo and in vitro conditions on the erythrocyte membrane lipids and its deformability. Ind J Biochem Biophys 1989; 26: 381-385.
30. 30 Jay RH, Rampling MW, Betteridge DJ. Abnormalities of blood rheology in familial hypercholesterolaemia: effects of treatment. Atherosclerosis 1990; 85: 249-256.
31. 31 Lijnen P, Celis H, Fagard R, Staessen J, Thijs L, Amery A. Influence of cholesterol lowering on plasma membrane lipids and cationic transport systems. J Hypertens 1994; 12: 59-64.
32. 32 Lijnen P, Petrov V, Amery A. Pravastatin has no direct effect on transmembrane cationic transport systems in human erythrocytes and platelets. Eur J Clin Pharmacol 1994; 47: 281-283.
33. 33 Tilvis RS, Taskinen MR, Miettinen TA. Effect of insulin treatment on fatty acids of plasma and erythrocyte membrane lipids in type 2 diabetes. Clin Chim Acta 1988; 17: 293-303.
34. 34 Juhan-Vague I, Rahmani-Jourdheuil D, Mishal Z, Roul C, Mourayre Y, Aillaud MF et al. Correction by insulin added in vitro of abnormal membrane fluidity of the erythrocytes from type 1 (insulin-dependent) diabetic patients. Diabetologia 1986; 29: 417-420.
35. 35 Candiloros H, Muller S, Zeghari N, Donner M, Drouin P, Ziegler O. Decreased erythrocyte membrane fluidity in poorly controlled IDDM. Diabetes Care 1995; 18: 549-551.
36. 36 Le Quan Sang KH, Mazeaud M, Astarie C, Duranthon V, Driss F, Devynck MA. Plasma lipids and platelet membrane fluidity in essential hypertension. Thromb Haemost 1993; 69: 70-76.
37. 37 Devynck MA. Do cell membrane dynamics participate in insulin resistance? Lancet 1995; 345: 336.